Is MOTS-c Safe? Safety Profile 2026 — PeptidePrices

Q: Is MOTS-c safe?

MOTS-c has a safety rating of 7/10 in our methodology — good. Endogenous mitochondrial peptide; human study showed safety in metabolic syndrome; promising early data

Q: Is MOTS-c FDA approved?

FDA status: Not FDA-approved. PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified MOTS-c?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest MOTS-c listings for prices ranked by COA tier and $/mg.

Safety Profile

MOTS-c

Updated today

Metabolic Peptide

7/10Good

How we score compound safety →

Primary use: Mitochondrial research

Regulatory Status

Not FDA-approved

Safety Summary

Endogenous mitochondrial peptide
human study showed safety in metabolic syndrome
promising early data

MOTS-c's 7/10 rating reflects mixed evidence — some clinical data and a meaningful research base, but enough open questions that researchers should weight personal risk tolerance heavily. Long-term safety in the population segment most likely to use this compound (off-label) is the area with the thinnest published evidence. Researchers often consider NAD+ and 5-Amino-1MQ as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeMitochondrial-derived peptide

Molecular Weight2,174.6 g/mol

Amino Acids16

SequenceMRWQEMGYIFYPRKLR

FormulaC₁₀₁H₁₅₂N₂₈O₂₂S₂

Storage

Lyophilized−20°C, stable long-term

Reconstituted2–8°C, use immediately

Extremely temperature sensitive
Degrades 85–90% at room temp within 2–3 hours
Store frozen until use
Reconstitute immediately before injection

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with MOTS-c

Full MOTS-c profile Cheapest MOTS-c deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.